Astrazeneca releases trial data on oral weight loss medication, with patients using the drug for four weeks experiencing nearly a 6% weight reduction.
①Astrazeneca reported that its oral small molecule weight loss drug AZD5004/ECC5004 reduced the average weight of patients by 5.8% within four weeks in early studies, and showed good tolerability; ② Astrazeneca acquired the global exclusive rights to the drug from Creentech for 2 billion US dollars last year, which is currently in the clinical research stage.
Futu Morning Post | Countdown to the election! The panic index VIX is burning high and uncertainty is haunting the market nerves; Up nearly 13% after hours! Palantir raises full-year revenue guidance
Jpmorgan warns: If Trump wins on Wednesday, the Fed may pause the easing cycle as early as December; Will the US stock market hit new highs after the election? Jpmorgan: FOMO psychology boosts, S&P may hit 6100 points by the end of the year; US polls: Harris and Trump are neck and neck in key 'swing states'.
US stocks closed: Trump, Harris concept stocks rose together, Chinese concept stocks remained stable and rose.
1. The market is filled with a wait-and-see attitude, with all three major indexes collectively falling. 2. Trump's media technology group rebounded after hitting bottom. 3. Photovoltaic and clean energy concept stocks strengthened collectively. 4. Reports claim that Nvidia will distribute Super Micro Computer orders to other suppliers.
UBS Reaffirms Their Sell Rating on AstraZeneca (AZN)
Sector Update: Health Care Stocks Softer in Afternoon Trading
AstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss Drug